TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodifie… Read more
TC Biopharm (Holdings) Plc (TCBWF) - Total Liabilities
Latest total liabilities as of June 2024: $4.87 Million USD
Based on the latest financial reports, TC Biopharm (Holdings) Plc (TCBWF) has total liabilities worth $4.87 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TC Biopharm (Holdings) Plc - Total Liabilities Trend (2020–2024)
This chart illustrates how TC Biopharm (Holdings) Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TC Biopharm (Holdings) Plc Competitors by Total Liabilities
The table below lists competitors of TC Biopharm (Holdings) Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Great Elm Group Inc
NASDAQ:GEG
|
USA | $75.80 Million |
|
G-Able PCL
BK:GABLE
|
Thailand | ฿3.89 Billion |
|
Vincit Group Oyj
HE:VINCIT
|
Finland | €23.49 Million |
|
Ant Precision Industry Co Ltd
TWO:3646
|
Taiwan | NT$434.24 Million |
|
Taiwan Taffeta Fabric Co Ltd
TW:1454
|
Taiwan | NT$603.66 Million |
|
Bayu Buana Tbk
JK:BAYU
|
Indonesia | Rp367.52 Billion |
|
DMS Propertindo Tbk PT
JK:KOTA
|
Indonesia | Rp471.84 Billion |
|
Premium Snacks Nordic AB
ST:SNX
|
Sweden | Skr132.05 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down TC Biopharm (Holdings) Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TC Biopharm (Holdings) Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TC Biopharm (Holdings) Plc (2020–2024)
The table below shows the annual total liabilities of TC Biopharm (Holdings) Plc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.32 Million | -14.85% |
| 2023-12-31 | $6.25 Million | -43.01% |
| 2022-12-31 | $10.96 Million | -55.41% |
| 2021-12-31 | $24.58 Million | +131.61% |
| 2020-12-31 | $10.61 Million | -- |